PR Newswire PHILADELPHIA, Nov. 15, 2024 PHILADELPHIA, Nov. 15, 2024 /PRNewswire/ -- Immunovia (NASDAQ Stockholm: IMMNOV), the pancreatic cancer diagnostics company, will present results from the recently completed model-development study of ...
PR Newswire BETHESDA, Md., Nov. 12, 2024 Findings could point to new ways to treat RAS-driven cancers BETHESDA, Md., Nov. 12, 2024 /PRNewswire/ -- Researchers at the National Institutes of Health (NIH) and their collaborators have ...
PR Newswire SHANGHAI, Nov. 11, 2024 – The MANEUVER study met the primary endpoint with an objective response rate (ORR) at week 25 of 54.0% compared with 3.2% for placebo (p SHANGHAI, Nov. 11, 2024 /PRNewswire/ -- Abbisko today announced ...
PR Newswire HOUSTON and SAN DIEGO, Nov. 11, 2024 TAC01-CLDN18.2 was well tolerated, with no dose-limiting toxicities and a favorable safety profile in the first two cohorts of the ongoing trial A pancreatic cancer patient treated with ...
PR Newswire SAN FRANCISCO, Nov. 11, 2024 SAN FRANCISCO, Nov. 11, 2024 /PRNewswire/ -- Optic, a digital biology company redefining drug discovery with AI, announced a collaboration with Vindur Tx, an early-stage oncology therapeutics venture. ...
PR Newswire ARCADIA, Calif., Nov. 11, 2024 ARCADIA, Calif., Nov. 11, 2024 /PRNewswire/ -- Theragent Inc., a comprehensive CDMO focused on advancing next-generation cell-based therapies, has announced a significant milestone for both ...
PR Newswire LOS ANGELES, Nov. 11, 2024 LOS ANGELES, Nov. 11, 2024 /PRNewswire/ -- Stand Up To Cancer® (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a combination of two types of targeted ...
PR Newswire CRANFORD, N.J., Nov. 11, 2024 Study, in patients with solid tumors focusing on gynecological malignant tumors such as ovarian, endometrial, and cervical, nearing completion with three remaining subjects to be enrolled 27% ...
PR Newswire SAN DIEGO, Nov. 11, 2024 Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® in Patients with Solid Tumors ...
PR Newswire TARRYTOWN, N.Y., Nov. 9, 2024 -ST101 Phase 2 data demonstrates activation of the tumor immune microenvironment in glioblastoma (GBM)- -ST316 Phase 1 data demonstrates antagonism of ß-catenin-driven immune exclusion- ...
A new study reveals a key mechanism driving skin cancer. Researchers have identified a protein-ion channel interaction that fuels tumor growth. ( ) What is Melanoma Melanoma arising from pigment-producing cells known as melanocytes is the deadliest form of skin ...
While the Centers for Disease Control and Prevention (CDC) advises that reducing alcohol consumption or abstaining can lower cancer risk, data from the Annenberg Public Policy Center (APPC) reveal that fewer than half of Americans are aware that regular alcohol consumption increases the risk of developing cancer later in life. ...
Copper is a micronutrient that is essential for the body to perform biological functions. While copper is required for enzymatic activities, tumor cells require more copper than healthy cells for its growth. A new study from the Max Planck ...
Immunotherapy is a promising treatment that harnesses the immune system to combat cancer, but its effectiveness has been limited in treating gastrointestinal cancers. ...
Adding immunotherapy to neoadjuvant chemoradiation can improve survival and enable surgery in esophageal cancer, reveals research results published in a journal of the American Association for Cancer Research. Bottom Line In patients with unresectable, locally advanced esophageal cancer, the combination of radiation, chemotherapy, and immunotherapy increased the likelihood of tumors becoming surgically removable, leading to significantly better ...
Subscribe to our Free Newsletters!